| 摘要: |
| 血管生成抑制剂已被证明是一类有效的肿瘤治疗药物.概述了从单靶点、多靶点，到广谱血管生成抑制剂在临床上的应用；介绍了单克隆抗体、小分子和内源性的血管生成抑制剂及其相应靶点，讨论了新的靶点及有前景的新型血管生成抑制剂，希望为未来临床治疗提供切实的帮助. |
| 关键词: 肿瘤 血管生成 血管生成抑制剂 |
| DOI：10.3969/J.ISSN.1000-5137.2018.01.018 |
| 分类号: |
| 基金项目:江苏省自然科学基金（BK20130106） |
|
| Current clinical application progress in angiogenesis inhibitors |
|
Lu Yu
|
|
Nanjing Tianyi Bioscience Co. Ltd., Nanjing 210061, China
|
| Abstract: |
| Inhibition of angiogenesis is an established modality of cancer treatment.We summarized angiogenesis inhibitors of three modalities:single-target,multi-target and broad-spectrum agents.We discussed the clinical efficacy of monoclonal antibodies,small molecules,endogenous angiogenesis inhibitors and their molecular targets.The promising targets and antiangiogenic treatments were discussed as well.This reviewing article may offer practical help for cancer therapy in the future. |
| Key words: tumor angiogenesis angiogenesis inhibitors |
Editorial Board